Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk
Clinical course of HER-2 positive breast cancer patients


  • Domen Ribnikar
  • Špela Fink
  • Snježana Frković-Grazio Onkološki inštitut, Ljubljana
  • Hotimir Lešničar Onkološki inštitut, Ljubljana
  • Aleksander Sadikov


HER-2 positive breast cancer, breast cancer


Ni abstrakta.

Abstract (Eng)

Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p<0.001) in the multivariate model, ranking before nodal status, PR status and age of patients. We may conclude that patients with HER-2 positive disease have worse survival regardless ofnodal status.



How to Cite

Ribnikar, D., Fink, Špela, Frković-Grazio, S., Lešničar, H., & Sadikov, A. (2008). Clinical course of HER-2 positive breast cancer patients. Onkologija : A Medical-Scientific Journal, 12(2), 94–98. Retrieved from https://revijaonkologija.si/Onkologija/article/view/393



Original Scientific Article